Literature DB >> 14100156

DANGEROUS POTENTIATION OF MEPERIDINE HYDROCHLORIDE BY PARGYLINE HYDROCHLORIDE.

I M VIGRAN.   

Abstract

Entities:  

Keywords:  ANTIHYPERTENSIVE AGENTS; HYPOTENSION, ORTHOSTATIC; MEPERIDINE; MONOAMINE OXIDASE INHIBITORS; PARGYLINE; PHARMACOLOGY; TOXICOLOGIC REPORT

Mesh：

Substances：

Year:  1964        PMID： 14100156     DOI： 10.1001/jama.1964.03060250071021

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

1.  The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder.

Authors:  Lois Jessen; Lawrence J Kovalick; Albert J Azzaro
Journal:  P T       Date:  2008-04

2.  Drug interactions with antihypertensive drugs.

Authors:  J E Crook; A S Nies
Journal:  Drugs       Date:  1978-01       Impact factor: 9.546

3.  Conscious-sedation in a patient on combined tranylcypromine and lithium therapy--a case report.

Authors:  J D Freilich; C R Bennett
Journal:  Anesth Prog       Date:  1983 May-Jun

4.  Anaesthetic management of labour and delivery in a woman taking long-term MAOI.

Authors:  T J Pavy; A P Kliffer; M J Douglas
Journal:  Can J Anaesth       Date:  1995-07       Impact factor: 5.063

Review 5.  Pharmacokinetic drug interactions in anaesthetic practice.

Authors:  M Wood
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

6.  Analysis of the inhibition of pethidine N-demethylation by monoamine oxidase inhibitors and some other drugs with special reference to drug interactions in man.

Authors:  B Clark; J W Thompson; G Widdrington
Journal:  Br J Pharmacol       Date:  1972-01       Impact factor: 8.739

Review 7.  Drug interactions of clinical significance with opioid analgesics.

Authors:  P M Maurer; R R Bartkowski
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 8.  The serotonin syndrome. Implicated drugs, pathophysiology and management.

Authors:  K A Sporer
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.